UNIONPAY
29.7.2020 10:02:43 CEST | Business Wire | Press release
UnionPay International, the card payment organisation with the world’s largest cardholder base, today announces a partnership with Glovo, the Barcelona-based on-demand economy technology start-up, which enables UnionPay cardholders to use its app initially in Spain, Portugal, France and Italy.
Founded in 2015, Glovo is an on-demand economy technology start-up that allows local stores to offer their products in the same city through the GLOVO App and supports intermediates in the delivery of such products. It is currently present in 22 countries including Croatia, France, Georgia, Italy, Poland, Portugal, Romania, Serbia, Spain and Ukraine.
This new partnership with Glovo enables UnionPay cardholders to make a wider range of purchases without the need to leave home. To encourage take up of the service while some lockdown measures are still in place, UnionPay customers have been offered free delivery until 15 August in Spain, Portugal and France.
UnionPay acceptance in France, Italy, Portugal and Spain has grown significantly in the last 12 months with a large number of online and offline merchants now accepting UnionPay cards. UnionPay’s cardholder base comprises Chinese ex-pats living and working in Europe, students from Asian countries, as well as a rapidly increasing domestic customer base among European nationals. This is particularly the case in Portugal where last year Millennium bcp became the first European bank to issue UnionPay cards.
Wei Zhihong, UnionPay International’s Market Director and Head of Europe said : “As one of the largest bankcard schemes worldwide, we are committed to providing payment ease for our cardholders. In this difficult time, we are making an extra effort, together with our partners, to offer safer and easier services to support our cardholders in Europe. We are very pleased to have reached a partnership with one of the world’s leading on-demand economy technology start-ups. Glovo is a company which has grown rapidly since its foundation in 2015 and through this new partnership the reach of its app is extended to our cardholders.
“With consumer behaviour changing as a result of COVID-19, more people are staying indoors and making purchases. This new partnership will enable our customers to benefit from Glovo’s platform and service, making purchases and arranging pick-ups without having to leave their own home. We are happy that we have been able to agree a delivery fee free period with Glovo to help keep costs down for cardholders. We look forward to announcing many more similar partnerships in the very near future.”
Sacha Michaud, Co-founder of Glovo said: “We are delighted to have reached a new partnership with UnionPay and hope that it represents the beginning of a long-term relationship which will benefit UnionPay card holders throughout France, Italy, Portugal and Spain. We look forward to working together on further partnerships as we move forward.”
With over 8.4 billion cards accumulatively issued worldwide, UnionPay is the card payment organisation with the world’s largest cardholder base. Its global network extends to 179 countries and regions, covering over 52 million merchants and more than 2.9 million ATMs worldwide.
- Ends -
About UnionPay International
UnionPay International (UPI) is a subsidiary of China UnionPay focused on the growth and support of UnionPay’s global business. In partnership with more than 2300 institutions worldwide, UnionPay
International has enabled card acceptance in 179 countries and regions with issuance in 61 countries and regions. UnionPay International provides high quality, cost effective and secure cross-border payment services to the world’s largest cardholder base and ensures convenient local services to a growing number of global UnionPay cardholders and merchants.
For more information, please visit: www.unionpayintl.com/en
For media enquiries please contact:
Citigate Dewe Rogerson
Oliver Parry/ Brandon Stockwell/ Patrick Evans
unionpay@citigatedewerogerson.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200729005031/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom